/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
CorMedix (CRMD) generated about $462 million in revenue and $187 million in net income (a 40.5% net margin) over the trailing twelve months, growing at roughly 305.8% a year. Figures are from SEC filings; this is analysis, not investment advice.
CorMedix generated about $462 million in revenue over the trailing twelve months. Revenue has grown at roughly 305.8% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Yes, CorMedix reported about $187 million in net income over the trailing twelve months, a net profit margin of roughly 40.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
CorMedix runs a gross margin of about 82.8%, an operating margin of about 47.0%, a net margin of about 40.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
CorMedix's revenue has compounded at roughly 305.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside CRMD's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Fiscal year ends Dec.